[Market Focus] Hanmi Pharmaceutical Soars Over 9% on News of Obesity Drug Supply to Mexico
Hanmi Pharmaceutical's stock price surged significantly following news that the company will supply obesity medications and other products to Mexico.
As of 3:07 p.m. on January 28, Hanmi Pharmaceutical was trading at 521,500 won, up 9.79% from the previous trading day. At one point during the session, the price rose to as high as 550,000 won.
On this day, Hanmi Pharmaceutical announced that it had signed an exclusive distribution agreement with Mexican pharmaceutical company Sanfer for the GLP-1 obesity treatment efeglenatide and the diabetes combination drug Daparon Family.
Under the agreement, Hanmi Pharmaceutical will supply finished products of efeglenatide and Daparon Family (Daparon tablets and Daparon Duo extended-release tablets), while Sanfer will be responsible for obtaining regulatory approval, marketing, distribution, and sales within Mexico.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Mexico is known as a country with a high obesity rate, with a prevalence of 36.86%. The diabetes prevalence rate is also 16.4%.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.